Real-World Evidence Supports Outpatient Axicabtagene Ciloleucel (Yescarta) Administration for Relapsed/Refractory LBCL
Real-World Evidence Supports Outpatient Axicabtagene Ciloleucel (Yescarta) Administration for Relapsed/Refractory LBCL

Sawyer Bawek, DO

The Impact of Novel Agents in Non-Hodgkin Lymphoma Treatment
The Impact of Novel Agents in Non-Hodgkin Lymphoma Treatment

Anuja V. Abhyankar, MD

Management of Multiple Myeloma: From Newly Diagnosed to Relapsed/Refractory Disease
Management of Multiple Myeloma: From Newly Diagnosed to Relapsed/Refractory Disease

Vaishali Deenadayalan, MD